Roche

Strategic intent

Roche is a global pioneer in pharmaceuticals and diagnostics, focused on advancing science to develop innovative medicines and diagnostic tests for oncology, immunology, infectious diseases, ophthalmology, and neuroscience.

Key market signals

• 2024-07: Roche reports positive Phase I data for oral obesity candidate CT-996, accelerating its entry into the highly lucrative metabolic disease market.
• 2024-09: US FDA approves Ocrevus Zunovo, a subcutaneous injection for multiple sclerosis, expanding Roche's neurology portfolio and improving patient administration times.
• 2024-10: US FDA approves Itovebi (inavolisib) for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
• 2025-01: Roche reports full-year 2024 financial results, confirming a return to strong base business growth following the decline of pandemic-era sales.

Financial health

• Roche reported full-year 2024 Group sales of CHF 58.3 billion, representing mid-single-digit growth at constant exchange rates, successfully offsetting the loss of COVID-19 related revenues. (Source: https://www.roche.com/investors)
• Core operating profit remained highly robust in 2024, supporting a continued increase in the annual dividend and demonstrating strong underlying business performance. (Source: https://www.roche.com/investors)

Impact & compliance

Legal & risks

Over the last 24 months, Roche has faced standard pharmaceutical industry legal risks, including patent infringement litigation regarding its blockbuster drugs, scrutiny over drug pricing under the US Inflation Reduction Act (IRA), and ongoing regulatory compliance audits across its global manufactu

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.